Chen et al. (2019) discovered that activation of the DNA damage response/TP53 pathway could lead to development of dilated cardiomyopathy. Rouhi et al. (Rouhi et al., 2022) demonstrated that the TP53 pathway was activated in human hearts with arrhythmogenic cardiomyopathy in the absence of overt cardiac failure. Shoffner et al. (Shoffner et al., 2020) discovered that inhibiting TP53 expression promoted cardiomyocyte proliferation during regeneration of zebrafish hearts. Here, TP53 is linked to heart failure.